ANDA 219859, held by Graviti Pharmaceuticals. Losartan Potassium.
As of Nov 21, 2026, ANDA 219859 (Losartan Potassium), held by Graviti Pharmaceuticals, was first approved by FDA on Sep 19, 2025, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 19, 2025 | Original application | Approved | None posted |
| Losartan Potassium25MG · tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium50MG · tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium100MG · tablet;oral | Losartan Potassium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters